GRAIL (GRAL) Stock Overview
A commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
GRAL Community Fair Values
Create NarrativeSee what 13 others think this stock is worth. Follow their fair value or set your own to get alerts.
100% Patient Improvement in trial puts this $16M Biotech on the radar
Key Takeaways Hoth is a clinical-stage biotech with a diversified pipeline across oncology, neurology, and inflammation. Lead drug HT-001 targets cancer treatment related rashes, a multi-hundred-million-dollar niche where no approved therapies exist.
GRAIL, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$65.55 |
| 52 Week High | US$73.74 |
| 52 Week Low | US$12.33 |
| Beta | 0 |
| 1 Month Change | 77.58% |
| 3 Month Change | 46.14% |
| 1 Year Change | 403.03% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 379.83% |
Recent News & Updates
Recent updates
Grail: A Speculative Buy
Sep 30
Overvaluation Risks And NHS Trials Will Spur Future Resilience
Market optimism may overestimate Galleri's near-term adoption and pricing power due to regulatory, payer, and competitive pressures.GRAIL: Cash Burn And Commercialization Timeline Are Problematic
Jan 22Here's Why We're Watching GRAIL's (NASDAQ:GRAL) Cash Burn Situation
Dec 24
Grail: Lack Of Near Term Catalyst; Market Likely To Lose Interest Soon
Dec 16GRAIL: Post-Spinoff, Illumina Maintains Control And Incentive To Support Success
Sep 24GRAIL's Potential Turnaround: Seeking FDA Approval For Galleri
Sep 09Shareholder Returns
| GRAL | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 31.5% | 5.2% | 1.2% |
| 1Y | 403.0% | -0.3% | 17.9% |
Return vs Industry: GRAL exceeded the US Biotechs industry which returned -0.3% over the past year.
Return vs Market: GRAL exceeded the US Market which returned 17.9% over the past year.
Price Volatility
| GRAL volatility | |
|---|---|
| GRAL Average Weekly Movement | 10.5% |
| Biotechs Industry Average Movement | 10.3% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 17.3% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: GRAL has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: GRAL's weekly volatility has decreased from 16% to 10% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 1,000 | Bob Ragusa | grail.com |
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development.
GRAIL, Inc. Fundamentals Summary
| GRAL fundamental statistics | |
|---|---|
| Market cap | US$2.36b |
| Earnings (TTM) | -US$442.95m |
| Revenue (TTM) | US$134.29m |
Is GRAL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GRAL income statement (TTM) | |
|---|---|
| Revenue | US$134.29m |
| Cost of Revenue | US$210.19m |
| Gross Profit | -US$75.90m |
| Other Expenses | US$367.05m |
| Earnings | -US$442.95m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -12.29 |
| Gross Margin | -56.53% |
| Net Profit Margin | -329.86% |
| Debt/Equity Ratio | 0% |
How did GRAL perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/05 01:56 |
| End of Day Share Price | 2025/10/03 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
GRAIL, Inc. is covered by 5 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kyle Mikson | Canaccord Genuity |
| Subhalaxmi Nambi | Guggenheim Securities, LLC |
| Tejas Savant | Morgan Stanley |